TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact
背景

TST006

Claudin 18.2/PD-L1 Bi-specific (FIC)
Target:
Claudin 18.2/PD-L1 Bi-specific (FIC)
Indication:
Solid Tumors
Project Status:
Preclinical

TST006 is a bi-specific antibody targeting Claudin 18.2 and PD-L1, which has the potential for the treatment of Claudin 18.2-expressing cancer patients who are resistant to or refractory from Claudin 18.2 mAb or PD-1/PD-L1 mAb therapies, such as late-line gastric cancer patients, pancreatic cancer patients and others.


TOP